Adam S. Crystal M.D., Ph.D.
Net Worth
Last updated:
What is Adam S. Crystal M.D., Ph.D. net worth?
The estimated net worth of Dr. Adam S. Crystal M.D., Ph.D. is at least $5,060,548 as of 30 Jan 2023. He owns shares worth $43,988 as insider, has earned $2,370,360 from insider trading and has received compensation worth at least $2,646,200 in C4 Therapeutics, Inc..
What is the salary of Adam S. Crystal M.D., Ph.D.?
Dr. Adam S. Crystal M.D., Ph.D. salary is $661,550 per year as Chief Medical Officer in C4 Therapeutics, Inc..
How old is Adam S. Crystal M.D., Ph.D.?
Dr. Adam S. Crystal M.D., Ph.D. is 48 years old, born in 1977.
What stocks does Adam S. Crystal M.D., Ph.D. currently own?
As insider, Dr. Adam S. Crystal M.D., Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | Chief Medical Officer | 16,054 | $2.74 | $43,988 |
What does C4 Therapeutics, Inc. do?
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Adam S. Crystal M.D., Ph.D. insider trading
C4 Therapeutics, Inc.
Dr. Adam S. Crystal M.D., Ph.D. has made 6 insider trades between 2021-2023, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 30,000 units of CCCC stock on 5 Apr 2021. As of 30 Jan 2023 he still owns at least 16,054 units of CCCC stock.
C4 Therapeutics key executives
C4 Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Adam S. Crystal M.D., Ph.D. (48) Chief Medical Officer
- Dr. Kenneth C. Anderson M.D., Ph.D. (74) Co-Founder, Independent Director & Member of Scientific Advisory Board
- Mr. Andrew J. Hirsch (54) Chief Executive Officer, Pres & Director
- Mr. Marc A. Cohen (62) Co-Founder, Executive Chairman & Sec.